Annual CFO
-$26.77 M
-$1.24 M-4.87%
December 31, 2023
Summary
- As of February 20, 2025, RGLS annual cash flow from operations is -$26.77 million, with the most recent change of -$1.24 million (-4.87%) on December 31, 2023.
- During the last 3 years, RGLS annual CFO has fallen by -$14.23 million (-113.53%).
- RGLS annual CFO is now -317.50% below its all-time high of $12.31 million, reached on December 31, 2010.
Performance
RGLS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$9.45 M
+$2.19 M+18.80%
September 30, 2024
Summary
- As of February 20, 2025, RGLS quarterly cash flow from operations is -$9.45 million, with the most recent change of +$2.19 million (+18.80%) on September 30, 2024.
- Over the past year, RGLS quarterly CFO has stayed the same.
- RGLS quarterly CFO is now -396.30% below its all-time high of $3.19 million, reached on December 31, 2020.
Performance
RGLS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$35.95 M
-$3.17 M-9.68%
September 30, 2024
Summary
- As of February 20, 2025, RGLS TTM cash flow from operations is -$35.95 million, with the most recent change of -$3.17 million (-9.68%) on September 30, 2024.
- Over the past year, RGLS TTM CFO has stayed the same.
- RGLS TTM CFO is now -601.11% below its all-time high of -$5.13 million, reached on March 31, 2012.
Performance
RGLS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RGLS Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.9% | 0.0% | 0.0% |
| 3 y3 years | -113.5% | -53.4% | -38.6% |
| 5 y5 years | +38.1% | -100.2% | -193.6% |
RGLS Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -10.9% | at low | -54.3% | +18.8% | -49.0% | at low |
| 5 y | 5-year | -113.5% | at low | -396.3% | +18.8% | -198.5% | at low |
| alltime | all time | -317.5% | +54.5% | -396.3% | +49.4% | -601.1% | +46.0% |
Regulus Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.45 M(-18.8%) | -$35.95 M(+9.7%) |
| Jun 2024 | - | -$11.64 M(+33.1%) | -$32.78 M(+19.7%) |
| Mar 2024 | - | -$8.74 M(+42.7%) | -$27.40 M(+2.3%) |
| Dec 2023 | -$26.77 M(+4.9%) | -$6.13 M(-2.4%) | -$26.77 M(-0.5%) |
| Sep 2023 | - | -$6.28 M(+0.4%) | -$26.90 M(-1.7%) |
| Jun 2023 | - | -$6.25 M(-22.9%) | -$27.35 M(+0.3%) |
| Mar 2023 | - | -$8.11 M(+29.8%) | -$27.26 M(+6.8%) |
| Dec 2022 | -$25.53 M(+5.8%) | -$6.25 M(-7.1%) | -$25.53 M(-5.8%) |
| Sep 2022 | - | -$6.73 M(+9.3%) | -$27.10 M(+4.5%) |
| Jun 2022 | - | -$6.16 M(-3.5%) | -$25.93 M(+4.6%) |
| Mar 2022 | - | -$6.38 M(-18.5%) | -$24.80 M(+2.8%) |
| Dec 2021 | -$24.13 M(+92.5%) | -$7.83 M(+40.8%) | -$24.13 M(+84.1%) |
| Sep 2021 | - | -$5.56 M(+10.7%) | -$13.11 M(+8.8%) |
| Jun 2021 | - | -$5.02 M(-12.0%) | -$12.04 M(-1.6%) |
| Mar 2021 | - | -$5.71 M(-279.1%) | -$12.24 M(-2.3%) |
| Dec 2020 | -$12.54 M(-36.8%) | $3.19 M(-170.9%) | -$12.54 M(-39.4%) |
| Sep 2020 | - | -$4.50 M(-13.9%) | -$20.70 M(-1.1%) |
| Jun 2020 | - | -$5.23 M(-12.9%) | -$20.93 M(-2.2%) |
| Mar 2020 | - | -$6.00 M(+20.6%) | -$21.39 M(+7.9%) |
| Dec 2019 | -$19.82 M(-54.2%) | -$4.98 M(+5.4%) | -$19.82 M(+5.1%) |
| Sep 2019 | - | -$4.72 M(-17.1%) | -$18.86 M(-26.3%) |
| Jun 2019 | - | -$5.69 M(+28.4%) | -$25.59 M(-20.3%) |
| Mar 2019 | - | -$4.43 M(+10.4%) | -$32.10 M(-25.8%) |
| Dec 2018 | -$43.27 M | -$4.02 M(-64.9%) | -$43.27 M(-14.1%) |
| Sep 2018 | - | -$11.45 M(-6.3%) | -$50.36 M(-0.4%) |
| Jun 2018 | - | -$12.21 M(-21.7%) | -$50.58 M(-9.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$15.60 M(+40.5%) | -$55.70 M(-5.2%) |
| Dec 2017 | -$58.77 M(+3.3%) | -$11.10 M(-4.8%) | -$58.77 M(-6.4%) |
| Sep 2017 | - | -$11.66 M(-32.7%) | -$62.78 M(-5.8%) |
| Jun 2017 | - | -$17.33 M(-7.2%) | -$66.61 M(-0.0%) |
| Mar 2017 | - | -$18.68 M(+23.7%) | -$66.63 M(+17.1%) |
| Dec 2016 | -$56.88 M(+14.1%) | -$15.11 M(-2.5%) | -$56.88 M(-3.3%) |
| Sep 2016 | - | -$15.50 M(-10.6%) | -$58.82 M(+6.7%) |
| Jun 2016 | - | -$17.34 M(+94.2%) | -$55.12 M(+15.9%) |
| Mar 2016 | - | -$8.93 M(-47.6%) | -$47.54 M(-4.7%) |
| Dec 2015 | -$49.86 M(+26.2%) | -$17.04 M(+44.4%) | -$49.86 M(+12.1%) |
| Sep 2015 | - | -$11.80 M(+20.9%) | -$44.47 M(+7.2%) |
| Jun 2015 | - | -$9.76 M(-13.2%) | -$41.47 M(-0.6%) |
| Mar 2015 | - | -$11.25 M(-3.5%) | -$41.73 M(+5.6%) |
| Dec 2014 | -$39.51 M(+39.5%) | -$11.66 M(+32.4%) | -$39.51 M(+6.3%) |
| Sep 2014 | - | -$8.80 M(-12.2%) | -$37.17 M(+13.3%) |
| Jun 2014 | - | -$10.02 M(+11.0%) | -$32.79 M(+8.6%) |
| Mar 2014 | - | -$9.03 M(-3.1%) | -$30.20 M(+6.6%) |
| Dec 2013 | -$28.33 M(+224.8%) | -$9.31 M(+110.3%) | -$28.33 M(+56.0%) |
| Sep 2013 | - | -$4.43 M(-40.4%) | -$18.16 M(+34.4%) |
| Jun 2013 | - | -$7.43 M(+3.9%) | -$13.51 M(+25.7%) |
| Mar 2013 | - | -$7.16 M(-940.8%) | -$10.75 M(+23.2%) |
| Dec 2012 | -$8.72 M(-42.1%) | $851.00 K(+278.2%) | -$8.72 M(-8.9%) |
| Sep 2012 | - | $225.00 K(-104.8%) | -$9.57 M(-2.3%) |
| Jun 2012 | - | -$4.67 M(-9.0%) | -$9.80 M(+91.0%) |
| Mar 2012 | - | -$5.13 M | -$5.13 M |
| Dec 2011 | -$15.06 M(-222.4%) | - | - |
| Dec 2010 | $12.31 M | - | - |
FAQ
- What is Regulus Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Regulus Therapeutics?
- What is Regulus Therapeutics annual CFO year-on-year change?
- What is Regulus Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly CFO year-on-year change?
- What is Regulus Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Regulus Therapeutics?
- What is Regulus Therapeutics TTM CFO year-on-year change?
What is Regulus Therapeutics annual cash flow from operations?
The current annual CFO of RGLS is -$26.77 M
What is the all time high annual CFO for Regulus Therapeutics?
Regulus Therapeutics all-time high annual cash flow from operations is $12.31 M
What is Regulus Therapeutics annual CFO year-on-year change?
Over the past year, RGLS annual cash flow from operations has changed by -$1.24 M (-4.87%)
What is Regulus Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RGLS is -$9.45 M
What is the all time high quarterly CFO for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly cash flow from operations is $3.19 M
What is Regulus Therapeutics quarterly CFO year-on-year change?
Over the past year, RGLS quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Regulus Therapeutics TTM cash flow from operations?
The current TTM CFO of RGLS is -$35.95 M
What is the all time high TTM CFO for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM cash flow from operations is -$5.13 M
What is Regulus Therapeutics TTM CFO year-on-year change?
Over the past year, RGLS TTM cash flow from operations has changed by $0.00 (0.00%)